Equity

Canada’s drug regulator issues final positive recommendation to support public reimbursement of Leqembi® (lecanemab) for early Alzheimer’s disease, marking a key policy shift.

Baidu has announced a dual-primary listing on the Main Board of the Hong Kong Stock Exchange, marking a strategic move for the company.

HUTCHMED announces significant progression-free survival gains in SANOVO trial combining ORPATHYS® and TAGRISSO® for MET-overexpressing EGFR-mutant lung cancer in China.

ChowChow Cloud International Holdings Limited issues a statement amid unusual market movements, details still emerging about the causes and implications.

A recent NATURE trial evaluating enVast-Assi in large-thrombus STEMI has reached its primary endpoint, marking a significant milestone in thrombectomy research.

HUTCHMED announces NMPA approval for ATLED® (Fanregratinib) to treat FGFR2-fusion intrahepatic cholangiocarcinoma, expanding options for this cancer type.

Mesoblast announces a significant increase in revenue, reaching US$120 million, driven by product sales and strategic partnerships, marking a key milestone.

Ovintiv reports significant increases in its Permian and Montney oil and gas reserves, signaling expansion in key resource plays.

Emirates Islamic Bank experiences a surge in international media mentions, highlighting increased global interest in its activities and strategic developments.

SalMar announces start of share buyback program to repurchase shares from the market, reflecting confidence in its future prospects.